IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Exploring AI In Patient-Centered Pharma Marketing For Alcohol Addicts And Smokers

[1]Shubham Kamdi, [2]Shruti Ganorkar, [3]Rushikesh Mamankar, [4]vaishnavi Talokar

[1]UG Student of Bachelor of Pharmacy, [2]Assistant Professor of Bachelor of Pharmacy, [3]UG Student of Bachelor of Pharmacy, [4]UG Student of Bachelor of Pharmacy

[1]Department of Pharmaceutics,

[1]Dr. Rajendra Gode Institute of Pharmacy, Amravati, India

Abstract: This paper explores the transformative potential of artificial intelligence (AI) integration within patient-centered pharmaceutical marketing strategies to address alcohol addiction and smoking cessation. As the pharmaceutical industry increasingly adopts patient-centric approaches, leveraging AI technologies offers novel avenues to enhance engagement and support for individuals battling addiction. The literature review encompasses global perspectives on AI regulation, AI-enabled clinical trials, patient engagement, drug discovery, and patient empowerment strategies. Objectives include increasing awareness, personalizing interventions, analyzing behavioral insights, enhancing patient engagement, and preventing relapse. Various AI tools such as digital therapeutics, chatbots, mobile apps, wearable devices, machine learning predictive models, cognitive behavioral therapy, neurofeedback training, virtual reality therapy, genetic testing, and social network analysis are discussed, alongside ethical considerations. The study proposes a qualitative research methodology involving a literature review, a survey of the study population, qualitative data analysis, and ethical considerations. Findings underscore the complexities and promises of AI-driven marketing strategies tailored to individuals dealing with addiction, providing recommendations for optimized strategies and ethical frameworks.

Key Words - Artificial intelligence, Patient-Centered marketing, pharmaceutical industry, alcohol addiction, smoking cessation, behavioral insights, data analysis, intervention strategies, ethical considerations.

INTRODUCTION

The pharmaceutical industry, a cornerstone of modern healthcare, is experiencing a remarkable evolution characterized by a pivot toward patient-centric marketing strategies. This transformation is intricately intertwined with the burgeoning integration of artificial intelligence (AI) technologies. The focal point of this project is to meticulously examine the profound implications of AI in reshaping pharmaceutical marketing paradigms. Through the adept utilization of machine learning algorithms and predictive analytics, pharmaceutical companies are empowered to craft bespoke marketing campaigns tailored to the unique needs and preferences of individual patients. This project endeavors to unravel the intricate web of AI's influence on pharmaceutical marketing by delving into tangible real-world case studies, navigating through the labyrinth of ethical considerations, and shedding light on the expansive ripple effects of AI on fostering patient-centered approaches within the pharmaceutical marketing landscape. [1]

The fundamental aim of this initiative is to highlight the potential of AI-driven methods in developing highly personalized and focused marketing campaigns within the pharmaceutical sector. By utilizing advanced machine learning algorithms and predictive analytics effectively, pharmaceutical companies can surpass traditional marketing limitations. This allows them to establish stronger connections with patients by delivering tailored messages and solutions that resonate with each individual.[2]

Using a variety of real-world examples across different therapeutic areas and market segments, the project aims to demonstrate the tangible effects of AI-powered marketing strategies in enhancing engagement, adherence, and ultimately, patient outcomes. From targeted digital advertisements to optimizing content dynamically and employing adaptive messaging frameworks, AI provides a versatile toolkit for pharmaceutical marketers to navigate the intricate landscape of modern healthcare with unprecedented flexibility and effectiveness.[3]

PATIENT-CENTRED AI INTERVENTION

Many AI therapies, each with advantages and disadvantages of its own, have been studied and created for alcohol addiction and smoking cessation. The individual's demands and preferences should be taken into account when choosing an AI tool for alcohol addiction or smoking cessation. [4-7] Here are some AI interventions that have been used:

Table 1. AI Interventions for Reliving Addiction Problems.

AI Intervention – Tool name	**Description**	**Advantages**	**Disadvantages**
Digital Therapeutics - **reSET®**	reSET® is a digital treatment platform utilizing evidence-based procedures such as cognitive behavioral therapy (CBT) for alcohol addiction/smoking cessation.	A personalized approach based on individual needs. Evidence-based techniques. Accessible anytime, anywhere.	Requires consistent user engagement. May not be suitable for severe addiction cases.
Chatbots and Virtual Assistants - **Woebot**	Woebot offers therapeutic interventions based on CBT principles for alcohol/smoking cessation through targeted dialogue and treatments.	24/7 availability. Anonymity and privacy. Tailored interventions.	Limited in-depth support. Lack of human interaction.
Mobile Apps - **Quit Genius**	Quit Genius is a mobile app providing personalized support for quitting smoking, including interactive modules, tracking tools, and a supportive community.	Convenient and accessible. Evidence-based content. Gamification elements for engagement.	May require consistent engagement. Limited effectiveness for severe addiction.
Wearable Devices - **SmartQuit**	SmartQuit utilizes AI algorithms and biofeedback to offer real-time remedies for smoking impulses, supported by a smartphone app for tracking and progress.	Real-time feedback and intervention. Individualized support. Data-driven insights.	Requires consistent wear and use. May not be suitable for all individuals.
Machine Learning Predictive Models - **PredictiMed**	PredictiMed identifies alcohol addiction relapse risk factors through machine learning, offering customized therapies based on patient data and electronic health records.	Early detection of relapse risk. Tailored interventions. Integration with healthcare systems.	Relies on data availability and quality. May have limitations in predicting relapse.
Computerized Cognitive Behavioral Therapy (CCBT) - **QuitNet**	QuitNet is an interactive CCBT tool providing structured modules for smoking cessation, including self-monitoring tools, behavioral exercises, and education.	Structured and evidence-based program. Interactive and engaging content. Accessible at any time.	Requires consistent engagement. May not be suitable for all individuals.

Neurofeedback Training - **BrainPaint**	BrainPaint utilizes neurofeedback training through EEG technology to provide real-time feedback on brain activity, aiding in reducing alcohol intake.	Individualized and targeted approach. Real-time feedback. Non-invasive and drug-free.	Requires specialized equipment and training. May not be accessible to all individuals.
Virtual Reality (VR) Therapy - **MindCotine**	MindCotine employs VR therapy for smoking cessation, offering immersive environments with mindfulness exercises and coping mechanisms.	Immersive and engaging experience. Exposure therapy in a controlled environment. Customizable and interactive content.	Requires VR equipment. Limited evidence for effectiveness.
Genetic Testing and Personalized Medicine - **GeneSight**	GeneSight analyses genetic profiles to personalize medication recommendations for alcoholism or smoking cessation, potentially improving treatment outcomes.	Personalized medication recommendations. Potential for improved treatment outcomes. Evidence-based approach.	Limited availability and access. Cost may be a barrier for some individuals.
Social Network Analysis - **Sober Grid**	Sober Grid employs AI algorithms for social network analysis to detect triggers and support sources for alcohol/tobacco addiction within social networks.	Targeted and personalized recommendations. Integration with social media platforms. Privacy and confidentiality protections.	Limited evidence for effectiveness. Relies on user engagement and data sharing.

BEHAVIORAL INSIGHTS

Effective interventions for alcohol addiction and smoking cessation rely heavily on understanding human behavior, encompassing psychological and social factors. Habit formation plays a crucial role, as both alcoholism and smoking are habitual behaviors shaped by cues, routines, and rewards. Disrupting these patterns through interventions that introduce healthier alternatives can yield positive outcomes. Additionally, social influence, including peer pressure and support networks, is key in addressing addictive behaviors; involving friends, family, or support groups in interventions can be effective. [8]

Cognitive biases, such as present bias and overconfidence, influence decision-making regarding addiction and can be targeted through cognitive-behavioral approaches or mindfulness practices. Emotional regulation skills are closely linked to addictive behaviors, making interventions focusing on enhancing emotional control, like mindfulness or reflective techniques, beneficial. [9]

Moreover, interventions must address self-efficacy and motivation through goal-setting and motivational interviewing to empower individuals toward change. Environmental factors, like the availability of alcohol or tobacco, significantly impact behavior and can be addressed through community campaigns or legislative measures to alter the context of addictive behaviors effectively. [10]

DATA ANALYSIS FOR ADDICTION INTERVENTION

Analyzing data for addiction intervention is complex due to the multifaceted nature of the disorder. Here are various approaches to examining the data:

1. **Quantitative Analysis:**
   - Demographic Analysis: Investigate trends or patterns in addiction rates by analyzing participant demographics like age, gender, and economic status.
   - Behavioral Patterns: Study behaviors such as amount, frequency, triggers, and cravings to understand the severity of addiction and potential treatment strategies.
   - Treatment Outcomes: Utilize statistical techniques to assess outcomes of treatment programs, such as reduced intake and quitting rates.

2. **Qualitative Analysis:**
   - Thematic Analysis: Gather qualitative insights from interviews or open-ended surveys, focusing on experiences, obstacles, and preferences.
   - Case Studies: Explore specific instances to comprehend factors influencing addiction and recovery.
3. **Mixed Methods Analysis:**
   - Triangulation: Combine quantitative and qualitative data for a comprehensive understanding of addiction and recovery.
   - Convergence and Expansion: Examine multiple data sources for validation and expansion of findings.
4. **Ethical Considerations:**
   - Anonymization: Protect participant identities by removing identifying details.
   - Informed Consent: Obtain consent before collecting data.
   - Privacy: Handle data confidentially.
5. **Reporting and Interpretation:**
   - Contextualize Findings: Analyze results in the context of existing research and theories.
   - Implications: Discuss implications for practice, policy, and future research.
   - Limitations: Acknowledge limitations such as sample size or data collection methods.

6. **Results Presentation:**
   - Visual Aids: Use tables, charts, and graphs to present data.
   - Quotations and Excerpts: Incorporate qualitative samples to illustrate conclusions.
   - Narrative Description: Provide context and meaning to findings.

Effective intervention strategies for addressing alcohol addiction and smoking cessation can be developed by integrating quantitative and qualitative methods while considering ethical considerations and applying behavioral insights. [11,12]

INTERVENTION STRATEGIES

AI has immense potential in pharmaceutical marketing, particularly for addressing alcohol addiction and smoking cessation through tailored strategies encompassing awareness, prevention, treatment, and aftercare. Here are several methods that could be applied:

a. **Personalized Messaging**: Utilize AI algorithms to analyze individual preferences, actions, and reactions, enabling pharmaceutical marketers to craft customized messages tailored to the needs of smokers and alcohol addicts. This personalized approach enhances engagement and effectiveness by highlighting relevant benefits such as health advantages, cost savings, or social acceptance.

b. **Real-time Support**: Implement AI-powered chatbots and virtual assistants to provide round-the-clock assistance, counselling, and motivation. These advanced programs can aid users in managing cravings, navigating challenging situations, and addressing withdrawal symptoms, ensuring support is readily available whenever needed.

c. **Gamification**: Incorporate gamification elements into interventions to enhance user motivation and engagement. Challenges, prizes, and progress tracking within a mobile application can make the process of quitting smoking or reducing alcohol consumption more enjoyable and satisfying, fostering a sense of accomplishment through virtual badges, leaderboards, and achievements.

d. **Analytics**: Employ AI systems to identify individuals at risk of relapse and offer personalized interventions. By analyzing behavioral patterns and triggers, the system can deliver timely assistance or reminders to users during vulnerable moments, potentially preventing relapse and promoting long-term behavior change.

e. **Behavioral Encouragements**: Leverage AI to apply behavioral science concepts, such as nudges, to promote desired behaviors. Timely reminders or prompts tailored to individual preferences and circumstances can effectively influence decision-making and facilitate behavior change.

f. **Community Support**: Utilize AI-powered systems to facilitate connections with online communities or peer support groups. By matching users based on shared experiences or backgrounds, these platforms foster a sense of community, accountability, motivation, and encouragement, enhancing the overall support network.

g. **Customized Treatment Plans**: AI systems can analyze patient characteristics and treatment experiences to develop personalized treatment plans. By considering lifestyle choices, psychological makeup, and genetic predispositions, the system can recommend interventions tailored to individual needs, improving the user experience and increasing the likelihood of success.

h. **Data-driven decision-making**: Harness vast datasets and advanced analytics to inform intervention tactics. AI can identify patterns, trends, and insights to optimize intervention strategies continuously, improving effectiveness based on user data and evidence-based practices.

In conclusion, AI-driven intervention techniques offer a personalized and comprehensive approach to assisting smokers and alcohol addicts in behavior change. By leveraging modern technology and behavioral science approaches, pharmaceutical marketers can deliver focused, effective, and user-centered interventions, resulting in significant outcomes. [13-15]

COLLABORATION WITH HEALTHCARE PROVIDERS

Cooperation with healthcare practitioners is essential for effectively marketing AI-driven therapies aimed at addressing alcohol addiction and smoking cessation. Effective marketing of AI-driven therapies for alcohol addiction and smoking cessation requires cooperation with healthcare practitioners. The following are some ways to work together with healthcare providers:

- **Identify key stakeholders**: Determine healthcare professionals who treat alcoholism and help patients quit smoking. Primary care doctors, addiction experts, counselors, and public health organizations are a few examples of these.
- **Engage in Dialogue**: Start a conversation with medical professionals to learn about their requirements, difficulties, and treatment decisions for addiction. Get their opinion on possible AI-driven interventions and how to incorporate them into their work.
- **Offer Training and Education**: Give healthcare professionals exposure to training and educational materials regarding the application of AI-driven therapies for the treatment of addiction. Workshops, webinars, or online seminars covering the basic principles of artificial intelligence (AI), the science behind addiction, and how AI could boost treatment outcomes are a few instances of this.
- **Highlight Value**: Use case studies and evidence-based research to show the importance of AI-driven treatments. Explain to medical professionals how these approaches can enhance patient outcomes, boost treatment adherence, and lower rates of recurrence.
- **Integrate into Clinical Practice**: Assist medical professionals in adopting AI-driven interventions into their day-to-day clinical work. This might involve developing principles for using AI in patient care, connecting AI tools to electronic health record systems, and offering ongoing assistance and resources.
- **Promote Collaboration**: Encourage a cooperative partnership between AI developers and healthcare providers. To guarantee that AI-driven interventions satisfy the needs of both patients and clinicians, and promote honest negotiation, open feedback, and teamwork.
- **Resolve Concerns**: Clarify any doubts or worries healthcare professionals may have regarding AI-driven therapies. Remove myths, offer information based on facts, and highlight the possible advantages of various actions.
- **Monitor and Examine**: Keep a continuous watch on and assess how well AI-driven healthcare interventions are working. Get patient and healthcare provider input, then modify the interventions as necessary to make them better.

Overall, we can ensure that AI-driven treatments for alcoholism and smoking cessation are successfully marketed and incorporated into clinical practice by working with healthcare professionals. This will ultimately enhance patient outcomes. [16-18]

COMMUNICATING CHANNEL & PATIENT FEEDBACK

Effectively promoting AI-driven therapies for alcohol addiction and smoking cessation involves setting up good communication channels with patients. Digital platforms like websites, social media, and mobile apps are great for sharing information about these therapies. Healthcare providers can use these platforms to share success stories, educational materials, and updates about treatment advances. This helps patients stay informed about their options and engaged in their treatment. [19]

Sending personalized emails is another helpful way to connect with patients interested in AI-driven interventions. Providers can send tailored newsletters with resources and guidance to support patients on their recovery journey. This direct communication helps patients feel connected and supported. Hosting virtual events, like webinars, gives patients a chance to interact with medical professionals and ask questions about

AI-driven therapies. These events help patients learn more about their treatment and feel more confident in their decisions. [20]

Patient portals are online communities where patients can share experiences and access information about their treatment. By creating a supportive environment, providers encourage patients to be active participants in their recovery. Using push notifications on mobile apps is a convenient way to engage patients and remind them to interact with their treatment program. These notifications can offer motivation and keep patients accountable. [20]

Feedback surveys are useful for gathering insights into patient experiences with AI-driven interventions. By collecting feedback, providers can understand patient satisfaction and areas for improvement. Offering one-on-one communication channels, like live chat or virtual consultations, gives patients personalized support when they need it. Providers can adapt to individual needs and preferences, improving the patient experience. [21]

Keeping patients informed about updates and enhancements to AI-driven interventions is important. This helps patients stay engaged and aware of the latest advancements in their treatment options. By using these communication channels and listening to patient input, healthcare providers can effectively promote AI-driven treatments for alcohol addiction and smoking cessation, meeting patient needs and achieving positive outcomes in addiction treatment. [20-21]

DATA SECURITY & ETHICS

In the promotion of AI-driven interventions for alcohol addiction and smoking cessation, ensuring data security and ethical considerations holds paramount importance. Firstly, safeguarding data privacy is imperative to prevent unauthorized access or breaches. This entails securely transmitting and storing patient data through encryption methods, adhering to relevant data protection laws such as HIPAA in the US and GDPR in Europe, thereby upholding patients' privacy rights. [22]

Secondly, obtaining informed consent from patients before collecting any personal or health-related data is crucial. Patients should be provided clear information about the purpose of data collection, its intended use, as well as associated risks or benefits. They should also retain the option to withdraw consent or opt out of data collection at any point. [22]

Thirdly, anonymizing or de-identifying patient data aids in protecting privacy by eliminating personally identifiable information (PII) from datasets, thus reducing the risk of re-identification. [23]

Transparency serves as another vital consideration, necessitating openness regarding the utilization of AI algorithms and their implications on patient care and treatment outcomes. Patients and healthcare professionals alike should be informed about potential biases and limitations inherent in AI-driven therapies. To mitigate bias, continuous auditing and validation of the data used for developing AI algorithms are essential. Techniques such as bias detection and algorithmic fairness evaluations aid in identifying and rectifying biases within AI models.

Clear delineation of data ownership and access rights among patients, healthcare providers, and AI developers is indispensable. Patients should possess control over their data, including the ability to view, modify, or delete their records. Ethical data usage involves employing patient data solely for the intended purpose of enhancing treatment outcomes and patient care, refraining from practices like targeted advertising or commercial exploitation without explicit consent. Implementing robust security measures, including firewalls, intrusion detection systems, and access controls, is crucial to safeguard against online threats and attacks. Regular software updates and patches are necessary to address known vulnerabilities and mitigate the risk of security breaches. [24]

Prioritizing ethical considerations and data security in the marketing of AI-driven therapies for alcohol addiction and smoking cessation is vital for cultivating trust with patients and healthcare providers while ensuring responsible utilization of patient data to enhance patient outcomes. [23,24]

FUTURE RESEARCH

In forthcoming research on AI applications for individuals dealing with smoking and alcohol addiction, several focal points are likely to emerge, all geared toward enhancing the efficacy and accessibility of interventions. Here are potential avenues for future exploration:

- **Personalized Treatment Approaches**: Investigating the utilization of AI to tailor treatment methods according to individual characteristics and requirements of smokers and alcohol addicts. This may involve creating algorithms capable of analyzing factors like genetics, behavior patterns, and social determinants of health to recommend personalized interventions with higher efficacy.

- **Predictive Analytics for Relapse Prevention**: Delving into advanced predictive analytics and machine learning algorithms to detect early indications of relapse among individuals grappling with smoking and alcohol addiction. Through the analysis of various data sources, including biometric data and behavioral patterns, researchers can develop models predicting relapse risk more accurately and offering timely interventions to prevent it.
- **Virtual Reality and Immersive Technologies**: Exploring the potential of virtual reality (VR) and immersive technologies in providing interventions for smoking cessation and alcohol addiction. Virtual environments can replicate real-life scenarios and triggers, offering patients opportunities to practice coping strategies and behavioral skills in a safe environment.
- **Remote Monitoring and Support Systems**: Investigating the development of AI-driven remote monitoring and support systems for continuous tracking of patients' progress and provision of real-time feedback and support. This may involve wearable devices, smartphone applications, and AI-powered chatbots providing personalized guidance and encouragement to individuals striving to quit smoking or decrease alcohol consumption.
- **Behavioral Economics and Incentive Mechanisms**: Applying principles from behavioral economics and gamification to design interventions incentivizing behavior change among smokers and alcohol addicts. AI algorithms can optimize incentive structures and reward systems to motivate sustained engagement with treatment programs and adherence to healthier behaviors.
- **Integration with Healthcare Systems**: Exploring strategies to integrate AI-driven interventions for smoking cessation and alcohol addiction into existing healthcare systems, including primary care settings, addiction treatment centers, and telehealth platforms. This may involve developing interoperable technologies connecting seamlessly with electronic health records, facilitating coordinated care across multiple providers and settings.
- **Ethical and Sociocultural Considerations**: Investigating the ethical implications of AI-driven interventions for smokers and alcohol addicts, encompassing issues related to privacy, equity, and autonomy. Future research should aim to ensure the deployment of AI technologies respects patients' rights and preferences while addressing disparities in access to care and treatment outcomes.
- **Longitudinal Studies and Outcome Evaluation**: Conducting longitudinal studies to evaluate the long-term effectiveness and durability of AI-driven interventions for smoking cessation and alcohol addiction. Researchers should assess not only short-term outcomes such as abstinence rates but also factors influencing sustained behavior change and quality of life over time.

In summary, future research on AI for smokers and alcohol addicts should prioritize the development of innovative, evidence-based interventions utilizing AI technologies to deliver personalized, scalable, and cost-effective solutions for individuals grappling with these dependencies. [25,26]

RESEARCH METHODOLOGY

1. Introduction:

Aim of the qualitative study: To explore the impact of AI on marketing strategies for individuals dealing with smoking and alcohol addiction.

In recent years, there has been a growing interest in utilizing Artificial Intelligence (AI) in healthcare, particularly concerning patient-centered pharmaceutical marketing. This qualitative study aims to explore the diverse impact of AI on marketing strategies tailored for individuals dealing with smoking and alcohol addiction. The study places a strong emphasis on understanding the perspectives and experiences of patients, healthcare professionals, and marketing experts.

To achieve this objective, the research methodology consists of two main components. Firstly, an extensive review of existing literature and journals is undertaken to comprehensively analyze insights related to AI's role in patient-centered pharmaceutical marketing for alcohol addiction and smoking cessation. This review involves a detailed examination of the literature, focusing on identifying the intricate nuances, challenges, and ethical considerations associated with utilizing AI-driven approaches in this field.

2. Survey of Study Population:

- Conducting the Survey: A researcher individually surveys the study population, focusing on individuals dealing with smoking addiction.
- The survey encompasses:
  - Use of Digital Aid.
  - Survey Year.

- Age groups.
- Sex.
- Frequency of Internet Access.
- Motivation to Stop.

- Each parameter is meticulously recorded and categorized for analysis.

3. Research Methodology Components:

- Literature Review:
  - Objective: To comprehensively analyze insights related to AI's role in patient-centered pharmaceutical marketing for alcohol addiction and smoking cessation.
- Detailed examination of existing literature focusing on:
  - Nuances of AI-driven approaches in healthcare marketing.
  - Challenges and ethical considerations.
- Qualitative Data Analysis:
  - Objective: To uncover underlying themes and patterns within the literature.
  - Methodologies used: thematic analysis.
  - Aim: To extract actionable insights and practical solutions for responsible integration of AI into pharmaceutical marketing plans, addressing ethical concerns and potential challenges.
- Findings and Recommendations:
  - Synthesizing insights from literature review, qualitative data analysis, and the survey of the study population.
  - Providing a comprehensive understanding of the transformative potential of AI in shaping patient-centered marketing strategies for smokers and alcohol addicts.
  - Offering practical recommendations for stakeholders interested in utilizing AI to improve health outcomes and empower patients within the field of addiction management.

4. Views and Interpretation:

- The individual survey conducted by the researcher ensures direct engagement with the study population, allowing for a deeper understanding of their behaviors and motivations regarding smoking addiction.
- Integration of survey data with literature review and qualitative analysis enriches the study, providing a robust foundation for insights and recommendations.
- Ethical considerations remain paramount throughout the research process, ensuring that the rights and privacy of participants are upheld.
- The findings serve as valuable guidance for stakeholders, informing the development of patient-centered marketing strategies that leverage AI to address smoking addiction effectively and ethically. [27,28]

MARKET SURVEY OF THE POPULATION

A. **Survey of Smokers:** this survey involves the population which are been smoking different king of drugs or substance for various reasons, following is the summarize resulted data of survey conducted.

Table.2. population study of Smokers

	Smokers (N = 2655)	**% used a digital aid in a recent attempt (n/N)**
Use Of Digital Aid		
Yes	833 (31.37%)	--
No	1822 (68.62%)	--
Survey Year		
2019	949 (35.74%)	11.80% (112/949)
2020	801 (30.16%)	15.85% (127/801)
2021	758 (28.54%)	13.06% (99/758)
2022	947 (35.66%)	10.77% (102/947)
Age		
16-24	695 (26.17%)	4.02 % (28/695)
25-34	830 (31.26%)	5.78 % (48/830)
35-44	625 (23.54%)	7.04 % (44/625)
45-54	602 (22.67%)	5.98 % (36/602)
55-64	445 (16.76%)	3.82 % (17/445)
65+	355 (13.37%)	2.53 % (9/355)
Sex		
Male	1452 (54.68%)	6.06% (88/1452)
female	1203 (45.31%)	2.82% (75/1203)
Frequency of Internet Access		
Never	235 (8.85%)	6.80% (16/235)
Rarely	263 (9.90%)	8.36% (22/263)
Frequently	2157 (81.24%)	15.25% (329/2157)
Motivation to Stop		
Low	1789 (67.38%)	6.98% (125/1789)
High	866 (32.61%)	7.85% (68/866)

B. **Survey of Alcohol Addicts/ High-Risk Drinkers:** This survey involves different people addicted to drinking for personal or different varying reason, following is the summarize data of survey conducted.

Table.2. population study of Alcohol Addicts/ High-Risk Drinkers

	Alcohol Addicts (N = 3122)	% used a digital aid in a recent attempt (n/N)
Use Of Digital Aid		
Yes	388 (12.42%)	--
No	2734 (87.57%)	--
Survey Year		
2019	1012 (32.41%)	6.32% (64/1012)
2020	854 (27.35%)	8.43% (72/854)
2021	983 (31.48%)	5.90% (58/983)
2022	902 (28.89%)	7.87% (71/902)
Age		
16-24	872 (27.93%)	6.99% (61/872)
25-34	910 (29.14%)	7.91% (72/910)
35-44	1008 (32.28%)	6.15% (62/1008)
45-54	1156 (37.02%)	8.99% (104/1156)
55-64	865 (27.70%)	3.23% (28/865)
65+	771 (24.69%)	2.85% (22/771)
Sex		
Male	1702 (54.51%)	6.58% (112/1702)
female	1420 (45.48%)	6.54% (93/1420)
Frequency of Internet Access		
Never	308 (9.93%)	7.46% (23/308)
Rarely	274 (8.77%)	5.83% (16/274)
Frequently	2540 (81.35%)	12.28% (312/2540)
Motivation to Stop		
Low	2016 (64.57%)	6.34% (128/2016)
High	1106 (35.42%)	5.69% (63/1106)

RESULT AND DISCUSSION

- **Survey of Smokers**

✓ Digital Aid Usage: 31.37% of smokers used a digital aid in a recent attempt.



Fig.1. Number of People Using Digital Aids.

✓ Survey Year: The usage of digital aids varied across survey years, with the highest usage in 2022 (35.66%).



Fig.2. Use of Digital Aids in Different Years with Varying Sample Size.

✓ Age Distribution: The majority of respondents were in the age group of 16-24 (26.17%) and 25-34 (31.26%).



Fig.3. Use of Digital Aids by Varying Groups of Age

✓ Sex: 54.68% of respondents were male, while 45.31% were female.



Fig.4. Use of Digital Aids by Males and Females.

✓ Frequency of Internet Access: 81.24% of smokers reported frequent Internet access.



Fig.5. Frequency of Internet Access by People for using Digital Aids.

✓ Motivation to Stop: 67.38% reported low motivation to stop smoking.



Fig.6. Number of People Motivated to Stop by Using Digital Aids.

- **Survey of Alcohol Addicts/High-Risk Drinkers**

✓ Digital Aid Usage: 12.42% of high-risk drinkers used a digital aid in a recent attempt.



Fig.7. Number of People Using Digital Aids.

✓ Survey Year: The usage of digital aids varied across survey years, with the highest usage in 2022 (7.87%).



Fig.8. Use of Digital Aids in Different Years with Varying Sample Size.

✓ Age Distribution: The highest proportion of respondents were in the age group of 45-54 (37.02%).



Fig.9. Use of Digital Aids by Varying Groups of Age.

✓ Sex: 54.51% of respondents were male, while 45.48% were female.



Fig.10. Use of Digital Aids by Males and Females.

✓ Frequency of Internet Access: 81.35% of high-risk drinkers reported frequent Internet access.



Fig.11. Frequency of Internet Access by People for using Digital Aids.

✓ Motivation to Stop: 64.57% reported low motivation to stop alcohol consumption.



Fig.12. Number of People Motivated to Stop by Using Digital Aids.

Discussion Over above Survey Study:

1. Implications for Marketing Strategies

The survey findings provide insights into the current landscape of AI-driven marketing strategies for individuals grappling with smoking and alcohol addiction. Notably, the relatively low adoption rates of digital aids for addiction cessation highlight challenges in effectively utilizing technology in this context. Variations observed across demographic groups, particularly in age and motivation levels, suggest the inadequacy of a one-size-fits-all approach. Instead, marketing strategies must be customized to address the specific needs and preferences of different segments within the target population.

Furthermore, the findings underscore the importance of acknowledging the multifaceted nature of addiction. Factors such as motivation to quit and frequency of internet access play significant roles in determining individuals' receptiveness to digital aids. Hence, marketing efforts should not only promote the availability of such aids but also address underlying barriers and concerns that may hinder their adoption.

2. Ethical Considerations

Apart from practical challenges, ethical considerations pose significant considerations in AI-driven marketing for addiction management. As technology increasingly integrates into healthcare, safeguarding patient privacy, autonomy, and informed consent becomes crucial.

Stringent measures are needed to prevent potential breaches of confidentiality and trust in the collection and use of personal data, particularly sensitive information related to addiction. Transparency regarding the algorithms and decision-making processes behind AI-driven interventions is essential to empower patients and alleviate concerns regarding algorithmic bias and accountability.

Conclusion of Survey Research

In conclusion, this research highlights the complexities of utilizing AI for marketing strategies tailored to individuals dealing with smoking and alcohol addiction. While technology offers promise in enhancing traditional interventions, its effective application requires a nuanced understanding of patient demographics, motivations, and ethical considerations. Bridging the gap between technological innovation and patient-centric care can pave the way for more personalized, effective, and ethically sound approaches to addiction management.

Recommendations from Survey Study:

1. Tailored Marketing Strategies

Based on the survey results, stakeholders should develop tailored marketing strategies that accommodate the diverse needs and preferences of individuals seeking assistance with addiction cessation. This may involve segmenting the target population based on demographic factors and crafting targeted messaging and interventions accordingly. By recognizing the diversity within the target audience, stakeholders can optimize engagement and adoption of AI-driven solutions.

2. Ethical Frameworks and Guidelines

Given the ethical considerations inherent in AI-driven marketing for addiction management, adherence to robust ethical frameworks and guidelines is imperative. This includes compliance with data protection regulations, obtaining informed consent, and transparent communication about the principles and methodologies underlying AI-driven interventions. Ongoing monitoring and evaluation are essential to identify and address any ethical concerns or unintended consequences.

3. Collaboration and Stakeholder Engagement

Lastly, fostering collaboration and engagement among diverse stakeholders is critical for the success of AI-driven marketing initiatives for addiction cessation. By leveraging collective expertise and insights, stakeholders can co-create solutions that are technically sophisticated, socially responsible, and culturally sensitive. Open dialogue and shared decision-making can advance the field toward a future where AI serves as a powerful tool for promoting health and well-being while upholding ethical standards and equity. [29,30]

CONCLUSION

This extensive investigation into the role of AI in patient-centered pharmaceutical marketing for alcohol addiction and smoking cessation reveals several significant findings and insights. It becomes apparent that AI has the potential to transform marketing strategies aimed at addressing addiction by offering personalized interventions, behavioral insights, and improved patient engagement. Nevertheless, the path to effective AI-driven interventions is fraught with complexities and obstacles, requiring a nuanced approach that incorporates ethical considerations, collaboration with healthcare providers, and tailored strategies.

The survey results yield valuable insights into the current landscape, illuminating both opportunities and challenges in the adoption of digital aids for addiction cessation. The low rates of adoption emphasize the necessity for customized marketing strategies that account for diverse demographic profiles, motivations, and concerns. Ethical considerations remain paramount, underscoring the need for robust frameworks to protect patient privacy, autonomy, and data security.

Looking ahead, stakeholders must prioritize collaboration, stakeholder engagement, and continuous evaluation to effectively navigate the complexities of AI-driven marketing for addiction management. By embracing personalized approaches, ethical frameworks, and collaborative partnerships, the pharmaceutical industry can harness the potential of AI to empower individuals, enhance treatment outcomes, and promote patient-centered care in the field of addiction cessation.
In Summary, this research underscores the transformative potential of AI in revolutionizing pharmaceutical marketing strategies for addiction management, while emphasizing the importance of responsible, patient-centric approaches guided by ethical principles and collaboration among stakeholders. As we navigate the dynamic landscape of healthcare, leveraging the capabilities of AI offers promise in addressing the intricate challenges of addiction and fostering holistic well-being.

REFERENCE

[1] Merceron, K., & Best, K. (2024). Integrating Professional Perspectives for AI Literacy: Empowering Students in an AI-Influenced Future. In The Role of Generative AI in the Communication Classroom (pp. 300-315). IGI Global.

[2] Chintalapati, S., & Pandey, S. K. (2022). Artificial intelligence in marketing: A systematic literature review. International Journal of Market Research, 64(1), 38-68.

[3] Venkatesan, R., & Lecinski, J. (2021). The AI marketing canvas: A five-stage road map to implementing artificial intelligence in marketing. Stanford University Press.

[4] Bedenkov, A., Moreno, C., Agustin, L., Jain, N., Newman, A., Feng, L., & Costello, G. (2021). Customer centricity in medical affairs needs human-centric artificial intelligence. Pharmaceutical Medicine, 35(1), 21-29.

[5] Bjerring, J. C., & Busch, J. (2021). Artificial intelligence and patient-centered decision-making. Philosophy & Technology, 34, 349-371.

[6] Czerska, I. (2023). Digital transformation in health care and its marketing dimension. Marketing of Scientific and Research Organizations, 49(3), 27-46.

[7] Ali Mohamad, T., Bastone, A., Bernhard, F., & Schiavone, F. (2023). How artificial intelligence impacts the competitive position of healthcare organizations. Journal of Organizational Change Management, 36(8), 49-70.

[8] Judah, G. D. (2015). An investigation into the psychological determinants of health habit formation (Doctoral dissertation, London School of Hygiene & Tropical Medicine).

[9] Ramey, T., & Regier, P. S. (2019). Cognitive impairment in substance use disorders. CNS spectrums, 24(1), 102-113.

[10] Reynolds, K. D., Spruijt-Metz, D., & Unge, J. (2008). Health behavior research and intervention. Maxcy-Rosenau-Last Public Health and Preventive Medicine: Fifteenth Edition (Public Health and Preventive Medicine (Maxcy-Rosenau)), 15, 941-951.

[11] Nahum-Shani, I., Ertefaie, A., Lu, X., Lynch, K. G., McKay, J. R., Oslin, D. W., & Almirall, D. (2017). A SMART data analysis method for constructing adaptive treatment strategies for substance use disorders. Addiction, 112(5), 901-909.

[12] Ainscough, T. S., McNeill, A., Strang, J., Calder, R., & Brose, L. S. (2017). Contingency management interventions for non-prescribed drug use during treatment for opiate addiction: a systematic review and meta-analysis. Drug and alcohol dependence, 178, 318-339.

[13] Torous, J., Bucci, S., Bell, I. H., Kessing, L. V., Faurholt-Jepsen, M., Whelan, P., ... & Firth, J. (2021). The growing field of digital psychiatry: current evidence and the future of apps, social media, chatbots, and virtual reality. World Psychiatry, 20(3), 318-335.

[14] Rawson, R. A., Obert, J. L., McCann, M. J., Castro, F. G., & Ling, W. (1991). Cocaine abuse treatment: A review of current strategies. Journal of Substance Abuse, 3(4), 457-491.

[15] Santosh, K. C., & Gaur, L. (2022). Artificial intelligence and machine learning in public healthcare: Opportunities and societal impact. Springer Nature.

[16] Jacob, L., Thomas, K. T., & Shukla, S. (2023). Potential Applications of AI and IoT Collaborative Framework for Health Care. The Role of AI, IoT and Blockchain in Mitigating the Impact of COVID-19, 69.

[17] Roy III, A. K., & Miller, M. M. (2012). The medicalization of addiction treatment professionals. Journal of Psychoactive Drugs, 44(2), 107-118.

[18] Yoast, R. A., Wilford, B. B., & Hayashi, S. W. (2008). Encouraging physicians to screen for and intervene in substance use disorders: obstacles and strategies for change. Journal of addictive diseases, 27(3), 77-97.

[19] Suggs, L. S. (2006). A 10-year retrospective of research in new technologies for health communication. Journal of health communication, 11(1), 61-74.

[20] Yoast, R. A., Wilford, B. B., & Hayashi, S. W. (2008). Encouraging physicians to screen for and intervene in substance use disorders: obstacles and strategies for change. Journal of addictive diseases, 27(3), 77-97.

[21] DiClemente, C. C., Schlundt, D., & Gemmell, L. (2004). Readiness and stages of change in addiction treatment. American journal on addictions, 13(2), 103-119.

[22] Silva, I., & Soto, M. (2022). Privacy-preserving data sharing in healthcare: An in-depth analysis of big data solutions and regulatory compliance. International Journal of Applied Health Care Analytics, 7(1), 14-23.

[23] Aggarwal, A., Tam, C. C., Wu, D., Li, X., & Qiao, S. (2023). Artificial intelligence–based chatbots for promoting health behavioral changes: systematic review. Journal of medical Internet research, 25, e40789.

[24] Santosh, K. C., & Gaur, L. (2022). Artificial intelligence and machine learning in public healthcare: Opportunities and societal impact. Springer Nature.

[25] Jacobson, N. C., Kowatsch, T., & Marsch, L. A. (Eds.). (2022). Digital therapeutics for mental health and addiction: The state of the science and vision for the future.

[26] Kazdin, A. E., & Blase, S. L. (2011). Rebooting psychotherapy research and practice to reduce the burden of mental illness. Perspectives on psychological science, 6(1), 21-37.

[27] Perski, O., Jackson, S. E., Garnett, C., West, R., & Brown, J. (2019). Trends in and factors associated with the adoption of digital aids for smoking cessation and alcohol reduction: a population survey in England. Drug and Alcohol Dependence, 205, 107653.

[28] Oldham, M., Beard, E., Loebenberg, G., Dinu, L., Angus, C., Burton, R., ... & Garnett, C. (2024). Effectiveness of a smartphone app (Drink Less) versus usual digital care for reducing alcohol consumption among increasing-and-higher-risk adult drinkers in the UK: a two-arm, parallel-group, double-blind, randomised controlled trial. EClinicalMedicine.

[29] Garnett, C., Oldham, M., Angus, C., Beard, E., Burton, R., Field, M., ... & Brown, J. (2021). Evaluating the effectiveness of the smartphone app, Drink Less, compared with the NHS alcohol advice webpage, for the reduction of alcohol consumption among hazardous and harmful adult drinkers in the UK at 6-month follow-up: protocol for a randomised controlled trial. Addiction, 116(2), 412-425.

[30] Beaulieu, T., Knight, R., Nolan, S., Quick, O., & Ti, L. (2021). Artificial intelligence interventions focused on opioid use disorders: A review of the gray literature. The American Journal of Drug and Alcohol Abuse, 47(1), 26-42.